Your browser doesn't support javascript.
loading
De novo variants in FBXO11 cause a syndromic form of intellectual disability with behavioral problems and dysmorphisms.
Jansen, Sandra; van der Werf, Ilse M; Innes, A Micheil; Afenjar, Alexandra; Agrawal, Pankaj B; Anderson, Ilse J; Atwal, Paldeep S; van Binsbergen, Ellen; van den Boogaard, Marie-José; Castiglia, Lucia; Coban-Akdemir, Zeynep H; van Dijck, Anke; Doummar, Diane; van Eerde, Albertien M; van Essen, Anthonie J; van Gassen, Koen L; Guillen Sacoto, Maria J; van Haelst, Mieke M; Iossifov, Ivan; Jackson, Jessica L; Judd, Elizabeth; Kaiwar, Charu; Keren, Boris; Klee, Eric W; Klein Wassink-Ruiter, Jolien S; Meuwissen, Marije E; Monaghan, Kristin G; de Munnik, Sonja A; Nava, Caroline; Ockeloen, Charlotte W; Pettinato, Rosa; Racher, Hilary; Rinne, Tuula; Romano, Corrado; Sanders, Victoria R; Schnur, Rhonda E; Smeets, Eric J; Stegmann, Alexander P A; Stray-Pedersen, Asbjørg; Sweetser, David A; Terhal, Paulien A; Tveten, Kristian; VanNoy, Grace E; de Vries, Petra F; Waxler, Jessica L; Willing, Marcia; Pfundt, Rolph; Veltman, Joris A; Kooy, R Frank; Vissers, Lisenka E L M.
Affiliation
  • Jansen S; Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
  • van der Werf IM; Department of Medical Genetics, University Hospital and University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.
  • Innes AM; Alberta Children's Hospital Research Institute and Department of Medical Genetics, Cumming School of Medicine, University of Calgary, 2888 Shaganappi Trail NW, Calgary, AB, T3B 6A8, Canada.
  • Afenjar A; Centre de Référence Déficiences Intellectuelles de Causes Rares, 75013, Paris, France.
  • Agrawal PB; APHP, GHUEP, Hôpital Armand Trousseau, Centre de Référence 'Malformations et maladies congénitales du cervelet', 75012, Paris, France.
  • Anderson IJ; Divisions of Genetics and Genomics and Newborn Medicine, Manton Center for Orphan Disease Research, Boston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Atwal PS; The University of Tennessee Genetics Center, Knoxville, TN, 37920, USA.
  • van Binsbergen E; Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL, 32224, USA.
  • van den Boogaard MJ; Department of Genetics, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
  • Castiglia L; Department of Genetics, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
  • Coban-Akdemir ZH; Laboratory of Medical Genetics, Oasi Research Institute, 94018, Troina, Italy.
  • van Dijck A; Baylor-Hopkins Center for Mendelian Genomics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Doummar D; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • van Eerde AM; Department of Medical Genetics, University Hospital and University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.
  • van Essen AJ; APHP, Service de Neurologie pédiatrique, Hôpital Armand Trousseau, Paris, France.
  • van Gassen KL; Sorbonne Université,GRC ConCer-LD, AP-HP, Hôpital Trousseau, Paris, France.
  • Guillen Sacoto MJ; Service de neuropediatrie, Hôpital Trousseau, 26 avenue du dr Arnold Netter, 75012, Paris, France.
  • van Haelst MM; Department of Genetics, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
  • Iossifov I; Department of Genetics, University of Groningen, University Medical Center Groningen (UMCG), 9700 RB, Groningen, The Netherlands.
  • Jackson JL; Department of Genetics, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
  • Judd E; GeneDx, Gaithersburg, MD, 20877, USA.
  • Kaiwar C; Department of Clinical Genetics, VU University Medical Center, 1081 HV, Amsterdam, The Netherlands.
  • Keren B; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY, 11724, USA.
  • Klee EW; New York Genome Center, New York, NY, 10013, USA.
  • Klein Wassink-Ruiter JS; Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL, 32224, USA.
  • Meuwissen ME; Department of Psychiatry, Washington University School of Medicine, St Louis, MO, 63110, USA.
  • Monaghan KG; Center for Individualized Medicine, Mayo Clinic, Scottsdale, AZ, 85259, USA.
  • de Munnik SA; Invitae, 1400 16th Street, San Francisco, CA, 94103, USA.
  • Nava C; Département de Génétique, APHP, GH Pitié-Salpêtrière, Paris, 75013, France.
  • Ockeloen CW; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
  • Pettinato R; Department of Genetics, University of Groningen, University Medical Center Groningen (UMCG), 9700 RB, Groningen, The Netherlands.
  • Racher H; Department of Medical Genetics, University Hospital and University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.
  • Rinne T; GeneDx, Gaithersburg, MD, 20877, USA.
  • Romano C; Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
  • Sanders VR; Département de Génétique, APHP, GH Pitié-Salpêtrière, Paris, 75013, France.
  • Schnur RE; INSERM, U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Universités, UPMC Université de Paris 06, 75013, Paris, France.
  • Smeets EJ; Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
  • Stegmann APA; Pediatrics and Medical Genetics, Oasi Research Institute - IRCCS, 94018, Troina, Italy.
  • Stray-Pedersen A; Alberta Children's Hospital Research Institute and Department of Medical Genetics, Cumming School of Medicine, University of Calgary, 2888 Shaganappi Trail NW, Calgary, AB, T3B 6A8, Canada.
  • Sweetser DA; Impact Genetics, 1100 Bennett Road, Bowmanville, ON, L1C 3K5, Canada.
  • Terhal PA; Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
  • Tveten K; Pediatrics and Medical Genetics, Oasi Research Institute - IRCCS, 94018, Troina, Italy.
  • VanNoy GE; Department of Pediatrics, Division of Genetics, Birth Defects and Metabolism, Ann and Robert H Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Chicago, IL, 60611, USA.
  • de Vries PF; GeneDx, Gaithersburg, MD, 20877, USA.
  • Waxler JL; Department of Clinical Genetics, Maastricht University Medical Centre, Universiteitssingel 50, 9229 ER, Maastricht, The Netherlands.
  • Willing M; Department of Clinical Genetics, Maastricht University Medical Centre, Universiteitssingel 50, 9229 ER, Maastricht, The Netherlands.
  • Pfundt R; Baylor-Hopkins Center for Mendelian Genomics, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Veltman JA; Norwegian National Unit for Newborn Screening, Department of Pediatric and Adolescent Medicine, Oslo University Hospital, Pb 4950 Nydalen, 0424, Oslo, Norway.
  • Kooy RF; Institute of Clinical Medicine, University of Oslo, 0318, Oslo, Norway.
  • Vissers LELM; Division of Medical Genetics, Massachusetts General Hospital for Children, Boston, MA, 02114, USA.
Eur J Hum Genet ; 27(5): 738-746, 2019 05.
Article in En | MEDLINE | ID: mdl-30679813
ABSTRACT
Determining pathogenicity of genomic variation identified by next-generation sequencing techniques can be supported by recurrent disruptive variants in the same gene in phenotypically similar individuals. However, interpretation of novel variants in a specific gene in individuals with mild-moderate intellectual disability (ID) without recognizable syndromic features can be challenging and reverse phenotyping is often required. We describe 24 individuals with a de novo disease-causing variant in, or partial deletion of, the F-box only protein 11 gene (FBXO11, also known as VIT1 and PRMT9). FBXO11 is part of the SCF (SKP1-cullin-F-box) complex, a multi-protein E3 ubiquitin-ligase complex catalyzing the ubiquitination of proteins destined for proteasomal degradation. Twenty-two variants were identified by next-generation sequencing, comprising 2 in-frame deletions, 11 missense variants, 1 canonical splice site variant, and 8 nonsense or frameshift variants leading to a truncated protein or degraded transcript. The remaining two variants were identified by array-comparative genomic hybridization and consisted of a partial deletion of FBXO11. All individuals had borderline to severe ID and behavioral problems (autism spectrum disorder, attention-deficit/hyperactivity disorder, anxiety, aggression) were observed in most of them. The most relevant common facial features included a thin upper lip and a broad prominent space between the paramedian peaks of the upper lip. Other features were hypotonia and hyperlaxity of the joints. We show that de novo variants in FBXO11 cause a syndromic form of ID. The current series show the power of reverse phenotyping in the interpretation of novel genetic variances in individuals who initially did not appear to have a clear recognizable phenotype.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Arginine N-Methyltransferases / Genetic Variation / Behavior / Abnormalities, Multiple / F-Box Proteins / Intellectual Disability Limits: Humans Language: En Journal: Eur J Hum Genet Journal subject: GENETICA MEDICA Year: 2019 Document type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Arginine N-Methyltransferases / Genetic Variation / Behavior / Abnormalities, Multiple / F-Box Proteins / Intellectual Disability Limits: Humans Language: En Journal: Eur J Hum Genet Journal subject: GENETICA MEDICA Year: 2019 Document type: Article Affiliation country: Netherlands